智通财经APP讯，上海医药(601607.SH)发布公告，基于对公司未来发展的信心，公司控股股东上实集 团计划在未来12个月内由其全资子公司上实国际，通过香港联合交易所有限公司系统以集中竞价方式增 持公司H股股份，增持股份总量5,500万股至7,400万股，不超过公司有投票权股份数的2%，本次增持不 设置固定价格区间，结合资本市场行情择机开展股票增持，资金来源为上实国际自有资金。 ...

格隆汇9月15日丨上海医药(601607.SH)公布，基于对公司未来发展的信心，公司控股股东上实集团计划 在未来12个月内由其全资子公司上实国际，通过香港联合交易所有限公司系统以集中竞价方式增持公司 H股股份，增持股份总量5,500万股至7,400万股,不超过公司有投票权股份数的2%，本次增持不设置固定 价格区间，结合资本市场行情择机开展股票增持，资金来源为上实国际自有资金。 ...

上海医药(601607.SH)公告称，公司控股股东上海实业（集团）有限公司计划在未来12个月内，由其全 资子公司上实国际投资有限公司通过香港联交所系统以集中竞价方式增持公司H股股份，增持股份总量 5500万股至7400万股，不超过公司有投票权股份数的2%。 ...

Core Viewpoint - The report from Citi expresses a structurally optimistic outlook for the Chinese pharmaceutical distribution industry despite the lack of a turnaround in the first half of the year [1] Group 1: Industry Insights - Potential easing of medical insurance expenditures is anticipated, which may positively impact the industry [1] - Possible optimization of centralized procurement policies is expected due to potential anti-involution measures in the healthcare sector [1] - Strengthening of direct cash settlement from medical insurance funds is noted as a positive development for the industry [1] - The domestic interest rate cut cycle is expected to improve the financial leverage of distributors [1] Group 2: Company Target Price Adjustments - The target price for China National Pharmaceutical Group (国药控股) is raised from HKD 20 to HKD 24.5 [1] - The target price for Shanghai Pharmaceuticals (上海医药) is increased from HKD 12.3 to HKD 14.2 [1] - The target price for China Resources Pharmaceutical (华润医药) is decreased from HKD 5.9 to HKD 5.6, while maintaining an "outperform" rating [1] - China National Pharmaceutical Group is identified as the preferred choice among pure distributors [1]

Core Viewpoint - The report from Credit Lyonnais indicates a structurally optimistic outlook for the Chinese pharmaceutical distribution industry despite the lack of a turnaround in the first half of the year [1] Industry Summary - Potential easing of medical insurance expenditures is anticipated, which could positively impact the industry [1] - Possible anti-involution measures in the healthcare sector are expected to optimize centralized procurement policies [1] - Strengthening of direct cash settlement from medical insurance funds is noted as a beneficial factor [1] - The domestic interest rate cut cycle is expected to improve the financial leverage of distributors [1] Company Summary - Credit Lyonnais raised the target price for China National Pharmaceutical Group (Sinopharm) from HKD 20 to HKD 24.5 [1] - The target price for Shanghai Pharmaceuticals' H-shares was increased from HKD 12.3 to HKD 14.2 [1] - The target price for China Resources Pharmaceutical was slightly decreased from HKD 5.9 to HKD 5.6, while maintaining an "outperform" rating [1] - Sinopharm is identified as the preferred choice among pure distributors by Credit Lyonnais [1]

Industry Overview - The pharmaceutical distribution industry serves as a critical link between pharmaceutical manufacturers and end consumers, characterized by a specialized division of labor [2][5] - The industry consists of upstream manufacturers producing various types of pharmaceutical products, including Western medicine, traditional Chinese medicine, medical devices, and chemical reagents [1] Cost Structure Analysis - The primary cost in the pharmaceutical distribution industry is sales cost, which includes product and raw material costs, accounting for approximately 95% of total sales costs, while other costs make up about 5% [5] Profitability Factors - Key drivers of profitability in the pharmaceutical distribution sector include sales scale and growth, gross margin levels, expense ratios, and inventory turnover [7] - Companies maintain stable gross margins through scale advantages and product structure adjustments, while controlling costs through refined management practices [7] Internet Integration - The integration of "Internet+" in the pharmaceutical distribution industry helps reduce costs and improve efficiency, allowing pharmaceutical companies to analyze order demands and pharmacies to manage inventory effectively [9] - Patients benefit from the ability to compare prices and brands online, facilitating informed purchasing decisions [9]

Drug Overview - Shanghai Pharmaceuticals has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole Tablets, allowing the product to be marketed in the Philippines [1] - Aripiprazole is an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and can also be used as an adjunct treatment for depression [1] - The drug was first approved by the FDA in the United States in November 2002 and was approved for domestic sale in China in October 2004 [1] Market Competition - In the Philippines, Aripiprazole Tablets face competition from five other companies, including OTSUKA PHARM, ZYDUS PHILS. INC., and MULTICARE PHARM [2] - The total sales revenue for Aripiprazole Tablets (10 mg) in the Philippines is projected to be $2.39 million in 2024 according to IQVIA data [3] Impact on Company - The approval of Aripiprazole Tablets in the Philippines is expected to positively impact the company's efforts to expand into overseas markets and accumulate valuable experience [4]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the Philippines Food and Drug Administration for the marketing of Aripiprazole tablets, an antipsychotic medication used for treating schizophrenia and manic episodes of bipolar disorder, and as an adjunct treatment for depression [1] Group 1 - The product approved is Aripiprazole tablets, which are primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder [1] - Aripiprazole can also be used as an adjunct treatment for depression [1] - The approval signifies a potential expansion of the company's product offerings in the pharmaceutical market [1]

智通财经APP讯，上海医药(02607)发布公告，近日，上海医药集团股份有限公司(以下简称"上海医 药"或"公司")下属上海上药中西制药有限公司(以下简称"上药中西")生产的阿立哌唑片(以下简称"该药 品")收到菲律宾食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。 阿立哌唑片是一种抗精神病药物，主要用于治疗精神分裂症和双相情感障碍的躁狂发作，也可作为抑郁 症的辅助治疗药物。由美国百时美-施贵宝公司和日本大冢公司研发，2002 年 11 月首次获得美国 FDA 批准上市(商品名 Abilify®)。 2004 年 10 月，上药中西的阿立哌唑片在国内获批上市;2021 年 3 月，阿 立哌唑片及阿立哌唑胶囊的 5mg 规格通过了仿制药一致性评价。截至本公告日，公司针对该药品在菲 律宾的上市投入注册相关费用约人民币 5 万元。 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 9 月 13 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於阿立呱唑片獲得菲律賓藥品註冊證書的公告》僅供 參閱。 上海医药集团股份有限公司 关于阿立 ...